Full Breakdown
President Trump's Executive Order Reclassifies Marijuana: Implications and Reactions
12/24/2025, 6:40:50 AM
Overview of the Reclassification
On December 18, 2025, President Donald Trump signed an executive order to reclassify marijuana from a Schedule I to a Schedule III substance under the Controlled Substances Act. This significant change acknowledges potential medical benefits of cannabis, which has long been categorized alongside drugs like heroin and LSD, deemed to have no accepted medical use and a high potential for abuse. The reclassification aims to facilitate more comprehensive research into marijuana's medical applications and could provide tax benefits for cannabis businesses.
Implications for Research and Industry
The reclassification is expected to ease restrictions on scientific research, allowing for more rigorous studies on the safety and efficacy of cannabis. Currently, researchers face significant hurdles due to the stringent regulations surrounding Schedule I substances. Ziva Cooper, director of the Center for Cannabis and Cannabinoids at UCLA, noted that the change could revolutionize public health by enabling better understanding of both the therapeutic and adverse effects of cannabis. The National Institutes of Health has already increased funding for cannabinoid research, with $75 million allocated for therapeutic studies in 2024.
Cannabis businesses stand to benefit financially as well. The reclassification allows companies to deduct standard business expenses, which were previously disallowed under IRS tax code Section 280E for Schedule I substances. This could significantly reduce the tax burden on cannabis firms, potentially leading to increased investment and growth within the industry.
Official Statements & Responses
Trump emphasized the need for this change, stating, “For decades this action has been requested by American patients suffering from extreme pain, incurable diseases, aggressive cancers, seizure disorders, neurological problems and more.” He clarified that the reclassification does not legalize marijuana federally but aims to enhance medical research.
In contrast, Jonathan Caulkins from Carnegie Mellon University expressed skepticism about the notion that U.S. laws have hindered cannabis research, pointing out that other countries do not face similar restrictions. Meanwhile, Susan Ferguson from the University of Washington highlighted that the reclassification would open the floodgates for clinical research, allowing for better tracking of cannabis formulations and their effects.
Criticism & Opposition
Despite the potential benefits, some critics remain cautious. Lt. Gov. Randy McNally of Tennessee stated he has “no interest” in changing the state's scheduling of marijuana, viewing it as a dangerous substance with limited medicinal efficacy. Additionally, concerns persist regarding the safety of cannabis products, particularly for vulnerable populations such as youth and those with mental health issues.
Conflicting Reports & Gaps
While many experts anticipate that the reclassification will lead to increased research and financial benefits for the cannabis industry, there are differing opinions on the implications for recreational use. Trump has made it clear that his administration does not support the legalization of recreational marijuana, which could limit the growth potential of the broader cannabis market.
What's Next
As the executive order directs the Attorney General to expedite the reclassification process, the cannabis industry and researchers await further developments. The outcome of this reclassification could reshape the landscape of cannabis research and regulation in the United States, potentially influencing state-level policies and public perception of marijuana use.
